NCT05334836 Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features
| NCT ID | NCT05334836 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Pancreatic Steatosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 236 participants |
| Start Date | 2022-04-06 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 236 participants in total. It began in 2022-04-06 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic cancer is the fifth leading cause of cancer mortality in Hong Kong and the seventh leading cause of cancer mortality worldwide. In 2020, approximately 496000 new cases of pancreatic cancers were diagnosed globally . Pancreatic cancer is a highly fatal cancer with a case-fatality rate of 94.0% globally. In Hong Kong, both the incidence and mortality of pancreatic cancer have increased over the past decade. Due to the deep-seated location of pancreas, it is difficult to diagnose pancreatic cancer at an early stage, which in turn leads to delays in cancer treatment and poorer survival. Despite advances in oncologic treatment, the 5-year survival rate of metastatic pancreatic cancer remains poor (\~2.9%). As such, there has been growing interest to improve pancreatic cancer prevention and survival by: 1. reduction of modifiable risk factors (eg, cigarette smoking, obesity, diabetes), 2. screening for early detection of high-risk pre-malignant lesions in selected high-risks patients with strong family history of pancreatic cancer and/or certain germline mutations of pancreatic cancer susceptibility genes (eg, BRCA1, BRAC2, DNA mismatch repair genes in Lynch Syndrome, etc) by magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS), and 3. surveillance of pre-malignant precursor lesions such as mucinous pancreatic cystic neoplasms (PCN) by imaging and/or EUS to identify high-risk neoplastic progression indicated for surgical resection.
Eligibility Criteria
Inclusion Criteria: 1. Age 18 or older 2. Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm; or healthy subjects. 3. Patients who are able to provide written informed consent to participate in the study and comply with the study procedures. Exclusion Criteria: 1. Unable to provide written informed consent 2. Patients with metallic implants or other contraindications to MRI 3. Patients with contraindications for endoscopy due to comorbidities 4. Patients with known pancreatic cancer or prior pancreatic resection 5. Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women
Contact & Investigator
Raymond S Tang, MD
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT05334836 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Steatosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05334836 currently recruiting?
Yes, NCT05334836 is actively recruiting participants. Contact the research team at felixsia@cuhk.edu.hk for enrollment information.
Where is the NCT05334836 trial being conducted?
This trial is being conducted at Shatin, Hong Kong.
Who is sponsoring the NCT05334836 clinical trial?
NCT05334836 is sponsored by Chinese University of Hong Kong. The principal investigator is Raymond S Tang, MD at Chinese University of Hong Kong. The trial plans to enroll 236 participants.